Tislelizumab: all 398 studies that test it

Page 3 of 4. Open to participants first (214), then studies with results posted, then the rest; newest registration first within each.

• A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingNCT04985721Phase 2
• Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCRecruitingNCT04973306Phase 2/3
• TACE Combined with Tislelizumab in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04954781Phase 2
• A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT04914390Phase 2
• A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CTRecruitingNCT04843267Phase 2
• Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
• PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian CancerRecruitingNCT04815408Phase 2
• A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach AdenocarcinomaRecruitingNCT04799548Phase 2
• Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCCRecruitingNCT04663035Phase 2
• Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecruitingNCT04615143Phase 2
• Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung CancerRecruitingNCT04542369Phase 2
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBCRecruitingNCT04501523Phase 2
• An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal CancerNot yet recruitingNCT04443543Phase 2
• Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsRecruitingNCT03736889Phase 2
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT05609370Phase 1/2Results posted
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedNCT05542342Phase 2Results posted
• Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Phase 2Results posted
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
• Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal CancerCompletedNCT05116085Phase 2Results posted
• To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsCompletedNCT05014828Phase 2Results posted
• Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerCompletedNCT04952597Phase 2Results posted
• Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Phase 3Results posted
• A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerTerminatedNCT04866017Phase 3Results posted
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Phase 3Results posted
• Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsCompletedNCT04716634Phase 2Results posted
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
• Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Phase 2Results posted
• A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerTerminatedNCT04363801Phase 2Results posted
• Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT04318080Phase 2Results posted
• Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
• Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedNCT04276493Phase 1/2Results posted
• Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal AntibodyCompletedNCT04068519Phase 1/2Results posted
• Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid TumorsCompletedNCT04047862Phase 1Results posted
• Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Phase 3Results posted
• Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT04004221Phase 2Results posted
• A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Phase 3Results posted
• A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Phase 1/2Results posted
• Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Phase 3Results posted
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Phase 3Results posted
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03777657Phase 3Results posted
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Phase 3Results posted
• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid TumorsCompletedNCT03744468Phase 1/2Results posted
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT03666143Phase 1Results posted
• A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Phase 3Results posted
• A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Phase 3Results posted
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 2Results posted
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Phase 3Results posted
• Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Phase 2Results posted
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Phase 3Results posted
• Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT03379259Phase 1/2Results posted
• Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Phase 3Results posted
• A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03209973Phase 2Results posted
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsCompletedNCT02660034Phase 1Results posted
• Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced TumorsCompletedNCT02407990Phase 1Results posted
• A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBCCompletedNCT07827079Phase 2
• A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyActive, not recruitingNCT07136077Phase 2
• A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT07010120Phase 1/2
• Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06914687Phase 2
• Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled StudyCompletedNCT06884670Phase 2
• Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT06866548Early Phase 1
• Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06673693Phase 2
• A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT06540066Phase 1
• Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous CarcinomaCompletedNCT06494189Phase 1
• A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid TumorsTerminatedNCT06487858Phase 1
• A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT06422520Phase 1
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT06396585Phase 2
• Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical TrialActive, not recruitingNCT06356597Phase 2
• Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal CancerCompletedNCT06333769Phase 2
• HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic CholangiocarcinomaActive, not recruitingNCT06239532Phase 2
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Phase 2
• Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon CancerActive, not recruitingNCT06124378Phase 2
• Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Phase 1
• Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCCStatus unknownNCT06059885Phase 2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Active, not recruitingNCT06009861Phase 2
• A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingNCT05984602Phase 1
• Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJCompletedNCT05941481Phase 2
• BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid TumorsTerminatedNCT05935098Phase 1
• A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05904496Phase 1
• PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal CancerCompletedNCT05880082Phase 2
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After SurgeryStatus unknownNCT05844371Phase 2
• Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasStatus unknownNCT05833984Phase 1/2
• Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast CancerWithdrawnNCT05809895Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCCCompletedNCT05807542Phase 2
• Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal CancerStatus unknownNCT05799443Phase 2
• Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.WithdrawnNCT05791097Phase 3
• A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05789069Phase 1
• Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompletedNCT05758116Phase 2
• Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal CancerWithdrawnNCT05690035Phase 2
• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruitingNCT05661955Phase 1/2
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT05651022Phase 1/2
• Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsWithdrawnNCT05644626Phase 1
• Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic CancerStatus unknownNCT05634564Phase 2
• ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Phase 1/2
• Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver FunctionsCompletedNCT05622071Phase 2
• Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyWithdrawnNCT05614453Phase 2
• Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)Status unknownNCT05603065Phase 4
• First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Phase 2

← Tislelizumab overview